News and Trends 1 Sep 2022
Provention Bio looks to advance diabetes drug through $125M loan
U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The BLA for teplizumab, Provention Bio’s lead investigational drug candidate, for the delay of progression to stage 3 clinical type 1 diabetes in at-risk individuals has […]